Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV to Present Pre-Clinical Proof-of-Concept Data on ALX-0761 at ACR
Ablynx NV announced that pre-clinical proof-of-concept data from ALX-0761, a Nanobody partnered with Merck Serono, will be presented at the Annual Meeting of the American College of Rheumatology (ACR), 26 to 30 October 2013, San Diego, California. The poster presentation will include data from in vivo experiments that assessed the efficacy of ALX-0761 in a cynomolgus monkey model that mimics human rheumatoid arthritis. In addition, total target levels of both IL-17A and IL-17F, pharmacodynamic biomarkers, immunogenicity and drug exposure were analyzed. The proof-of-concept results demonstrated that both IL-17A and IL-17F play a role in the onset and/or maintenance of rheumatoid arthritis and that ALX-0761 improved the clinical endpoints: X-ray score B (the score for bone erosion or architectural joint destruction accompanied by bone erosion) and the arthritis score (the total of the swelling scores of the individual joints). Furthermore, promising biomarkers were identified to aid further clinical development.
Latest Developments forAblynx NV
- Ablynx NV on track to start Phase III study in patients with acquired TTP in mid 2015
- Ablynx NV's anti-Il-6r nanobody partnered with Abbvie demonstrates a bioavailability of more than 80 pct after subcutaneous injection
- Ablynx NV's Anti-vwf Nanobody, Caplacizumab, achieves clinical proof-of-concept in Phase II Titan study
- Ablynx to present additional positive data on anti-IL-6R Nanobody ALX-0061
Latest Key Developments inBiotechnology
- Share this
- Digg this